Related references
Note: Only part of the references are listed.Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
J. R. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study
Mazyar Shadman et al.
LANCET HAEMATOLOGY (2023)
ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY
P. L. Zinzani et al.
HEMATOLOGICAL ONCOLOGY (2023)
LONG‐TERM FOLLOW‐UP OF MULTICENTER PHASE II TRIAL OF ZANUBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX (BOVEN) IN PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL
J. D. Soumerai et al.
HEMATOLOGICAL ONCOLOGY (2023)
Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities
Anna Maria Frustaci et al.
CANCERS (2023)
Bruton tyrosine kinase inhibitors in the management of Waldenstrom macroglobulinemia
Jorge J. Castillo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2023)
P631: CHARACTERIZATION OF ZANUBRUTINIB SAFETY/TOLERABILITY PROFILE AND COMPARISON WITH IBRUTINIB PROFILE IN PATIENTS WITH B-CELL MALIGNANCIES: POST HOC ANALYSIS OF A LARGE CLINICAL TRIAL SAFETY DATABASE
Jennifer R. Brown et al.
HemaSphere (2023)
P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY
Talha Munir et al.
HemaSphere (2023)
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
Constantine S. Tam et al.
BLOOD ADVANCES (2022)
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study
Yuqin Song et al.
BLOOD (2022)
A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies
Yuqin Song et al.
BRITISH JOURNAL OF HAEMATOLOGY (2022)
BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner
Javier L. Munoz et al.
CURRENT ONCOLOGY REPORTS (2022)
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
Paul M. Barr et al.
BLOOD ADVANCES (2022)
Global patterns of non-Hodgkin lymphoma in 2020
Allini Mafra et al.
INTERNATIONAL JOURNAL OF CANCER (2022)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022 Featured Updates to the NCCN Guidelines
William G. Wierda et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
Constantine S. Tam et al.
LANCET ONCOLOGY (2022)
Zanubrutinib in Treating Waldenstr?m Macroglobulinemia, the Last Shall Be the First
Anagha Deshpande et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2022)
Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
Piers Blombery et al.
BLOOD ADVANCES (2022)
Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial
Stephen Opat et al.
BLOOD (2022)
NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies
Anthony R. Mato et al.
BLOOD (2022)
Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study
Jennifer R. Brown et al.
BLOOD (2022)
Zanubrutinib in lymphoproliferative disorders: a comprehensive review
Javier Munoz et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2022)
Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients
Fuli Fan et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP
Ying C. Ou et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials
Keshu Zhou et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
B-Cell Lymphomas, Version 5.2021 Featured Updates to the NCCN Guidelines
Andrew D. Zelenetz et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
H. Yesid Estupinan et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
Susan M. O'Brien et al.
FRONTIERS IN ONCOLOGY (2021)
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma
Stephen Opat et al.
CLINICAL CANCER RESEARCH (2021)
A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenstrom Macroglobulinemia
Gang An et al.
CLINICAL CANCER RESEARCH (2021)
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
John C. Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma
Ying C. Ou et al.
LEUKEMIA & LYMPHOMA (2021)
Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib
Constantine S. Tam et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2021)
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma
Constantine S. Tam et al.
BLOOD ADVANCES (2021)
Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia
Tom A. Mulder et al.
HEMASPHERE (2021)
Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib
Jim S. Qin et al.
JOURNAL OF IMMUNOTHERAPY (2020)
Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase
Yuqin Song et al.
CLINICAL CANCER RESEARCH (2020)
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study
Wei Xu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Chronic lymphocytic leukemia in 2020: a surfeit of riches?
Sameer A. Parikh et al.
LEUKEMIA (2020)
Zanubrutinib for the treatment of patients with Waldenstrom macroglobulinemia: 3 years of follow-up
Judith Trotman et al.
BLOOD (2020)
Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase
Ling Xiao et al.
CIRCULATION (2020)
The Evolution of Targeted Therapies in Chronic Lymphocytic Leukaemia
Valentina Gianfelici et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2020)
Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma
Constantine S. Tam et al.
BLOOD ADVANCES (2020)
Nx-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies
Daniel W. Robbins et al.
BLOOD (2020)
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
Constantine S. Tam et al.
BLOOD (2019)
UPDATED SAFETY AND EFFICACY DATA IN THE PHASE 1 TRIAL OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB-3111)
C.S. Tam et al.
HEMATOLOGICAL ONCOLOGY (2019)
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
T. D. Shanafelt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment
Ryan M. Young et al.
IMMUNOLOGICAL REVIEWS (2019)
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
Yunhang Guo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
From Biology to Therapy: The CLL Success Story
Deyan Y. Yosifov et al.
HEMASPHERE (2019)
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
Michael Wang et al.
LANCET (2018)
Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy
Jan A. Burger et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
J. A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
NCCN Guidelines® Insights Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017 Featured Updates to the NCCN Guidelines
William G. Wierda et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib
Varinder Kaur et al.
ANNALS OF HEMATOLOGY (2017)
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
Ariela Noy et al.
BLOOD (2017)
Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma
Nakhle S. Saba et al.
BLOOD (2016)
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Joseph A. Fraietta et al.
BLOOD (2016)
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
Barbara Eichhorst et al.
LANCET ONCOLOGY (2016)
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
Asher Chanan-Khan et al.
LANCET ONCOLOGY (2016)
Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Constantine S. Tam et al.
BLOOD (2016)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2015
Andrew D. Zelenetz et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2015)
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies
Eleonora Marostica et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial
Constantine Tam et al.
BLOOD (2015)
Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia
Steven P. Treon et al.
BLOOD (2014)
Non-Hodgkin's Lymphomas, Version 4.2014
Andrew D. Zelenetz et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Promising Impact of Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, for the Management of Lymphoid Malignancies
Valkal Bhatt et al.
PHARMACOTHERAPY (2014)
Understanding, recognizing, and managing toxicities of targeted anticancer therapies
Grace K. Dy et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis
Munevver Cinar et al.
LEUKEMIA RESEARCH (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting B-cell receptor signaling: changing the paradigm
Nathan Fowler et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2013)
The B-cell receptor signaling pathway as a therapeutic target in CLL
Jennifer A. Woyach et al.
BLOOD (2012)
Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Colonel Bruton's Kinase Defined the Molecular Basis of X-Linked Agammaglobulinemia, the First Primary Immunodeficiency
Wasif N. Khan
JOURNAL OF IMMUNOLOGY (2012)
Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
Tadeusz Robak et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century
Hermann Brenner et al.
BLOOD (2008)
Bruton's tyrosine kinase as a new therapeutic target
Fatih M. Uckun et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2007)
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase
Zhengying Pan et al.
CHEMMEDCHEM (2007)
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
KR Rai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
